What the evidence says
Why the eyes need ophthalmology early
40 to 84%of SJS and TEN cases have ocular complications, which are often overlooked because of the severe systemic illness.Sotozono 2025, Allergology International, review
24 hoursfrom admission to the first ophthalmic examination and treatment, in the German S3 guideline, which also sets preservative free lubrication every 1 to 2 hours regardless of severity and early amniotic membrane for conjunctival epithelial defects.Paulmann 2024, JDDG, German S3 guideline, consensus recommendations
4 daysSteroid pulse therapy with 0.1% betamethasone eye drops started within four days of onset significantly reduces ocular sequelae, as set out in the Japanese treatment guidelines.Sotozono 2025, Allergology International, review
92% vs 33%of eyes had vision of 20/40 or better at last follow up with and without a protocol of focused exams, lubrication, topical steroids and antibiotics, and amniotic membrane. Vision threatening complications fell from 67% to 17%, and most occurred in the first 2 years.Shanbhag 2019, American Journal of Ophthalmology, retrospective comparative series, 48 patients
79 patientsgraded for acute ocular severity. Mild and moderate cases managed medically all reached 20/20 without scarring. Severe and extremely severe cases received urgent amniotic membrane: all severe cases reached 20/20, and 9 of 10 extremely severe cases did.Gregory 2016, Ophthalmology, prospective case series
The data are case series and cohorts rather than trials, but they consistently favor early ophthalmology, early anti-inflammatory therapy, and early amniotic membrane for severe disease.
Who is at risk of severe eye involvement
Under 30Patients younger than 30 were more likely to develop severe ocular complications, and patients with them tended to be female. Cold medicines including NSAIDs, and common cold symptoms before onset, were also associated.Ueta 2023, Frontiers in Medicine, international cohort, 682 patients from 13 hospitals
≥10%body surface area detachment predicted acute severe ocular complications, and age 60 or older was marginally predictive.Panpruk 2021, Scientific Reports, 47 patients
The two cohorts point in opposite directions on age, so age alone should not lower suspicion. The cold medicine and NSAID association is tied to TLR3 and EP3 susceptibility variants, and HLA class I genes have been linked to severe ocular complications.
Where practice differs
6 of 9French reference centers used corticosteroid or combined antibiotic corticosteroid drops in the acute phase. All requested prompt ophthalmology, and amniotic membrane was used according to the clinical course. The authors found the role of topical and systemic steroids not consensual, and advised restricting preservatives.Thorel 2020, Orphanet Journal of Rare Diseases, national audit and consensus
AntibioticsThe German guideline advises against prophylactic antibiotic drops without an epithelial defect. The Mass Eye and Ear protocol uses moxifloxacin with a topical steroid from the start.Paulmann 2024; Metcalfe 2021, Frontiers in Medicine, protocol review
2 of 10eyes had satisfactory surface reconstruction after chronic stage amniotic membrane with living related limbal and conjunctival allograft, with infection in 4.Gomes 2003, Archives of Ophthalmology, case series
Late reconstruction succeeds far less often than early control of the acute inflammation.
- Sotozono C, Ueta M. Updates on the ocular manifestations and treatment of SJS/TEN. Allergol Int. 2025;74(3):356-360. doi:10.1016/j.alit.2025.05.003
- Gregory DG. New grading system and treatment guidelines for the acute ocular manifestations of Stevens-Johnson syndrome. Ophthalmology. 2016;123(8):1653-1658. doi:10.1016/j.ophtha.2016.04.041
- Shanbhag SS, Rashad R, Chodosh J, Saeed HN. Long-term effect of a treatment protocol for acute ocular involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Ophthalmol. 2019;208:331-341. doi:10.1016/j.ajo.2019.07.006
- Panpruk R, Puangsricharern V, Klaewsongkram J, et al. Clinical parameters and biological markers associated with acute severe ocular complications in Stevens-Johnson syndrome and toxic epidermal necrolysis. Sci Rep. 2021;11(1):20275. doi:10.1038/s41598-021-99370-1
- Thorel D, Ingen-Housz-Oro S, Royer G, et al. Management of ocular involvement in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: French national audit of practices, literature review, and consensus agreement. Orphanet J Rare Dis. 2020;15(1):259. doi:10.1186/s13023-020-01538-x
- Paulmann M, Heuer R, Annecke T, et al. S3 guideline: diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis), part 2: supportive therapy of EN in the acute and post-acute stages. J Dtsch Dermatol Ges. 2024;22(11):1576-1593. doi:10.1111/ddg.15516
- Metcalfe D, Iqbal O, Chodosh J, Bouchard CS, Saeed HN. Acute and chronic management of ocular disease in Stevens Johnson syndrome/toxic epidermal necrolysis in the USA. Front Med (Lausanne). 2021;8:662897. doi:10.3389/fmed.2021.662897
- Hung SI, Mockenhaupt M, Blumenthal KG, et al. Severe cutaneous adverse reactions. Nat Rev Dis Primers. 2024;10(1):30. doi:10.1038/s41572-024-00514-0
- Gibson A, Ram R, Gangula R, et al. Multiomic single-cell sequencing defines tissue-specific responses in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Commun. 2024;15(1):8722. doi:10.1038/s41467-024-52990-3
- Ueta M, Inoue C, Nakata M, et al. Severe ocular complications of SJS/TEN and associations among pre-onset, acute, and chronic factors: a report from the international ophthalmology collaborative group. Front Med (Lausanne). 2023;10:1189140. doi:10.3389/fmed.2023.1189140
- Kannabiran C, Ueta M, Sangwan V, et al. Association of human leukocyte antigen class 1 genes with Stevens Johnson syndrome with severe ocular complications in an Indian population. Sci Rep. 2017;7(1):15960. doi:10.1038/s41598-017-15965-7
- Gomes JA, Santos MS, Ventura AS, et al. Amniotic membrane with living related corneal limbal/conjunctival allograft for ocular surface reconstruction in Stevens-Johnson syndrome. Arch Ophthalmol. 2003;121(10):1369-1374. doi:10.1001/archopht.121.10.1369
Written by Stephan Thomas Blaskovics, Columbia VP&S, MS3. Draft for committee review.